- Home
- ANL vs BYSI Comparison
ANL vs BYSI Comparison
Compare ANL & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANL
- BYSI
- Stock Information
- Founded
- ANL 2004
- BYSI 2010
- Country
- ANL Cayman Islands
- BYSI United States
- Employees
- ANL N/A
- BYSI N/A
- Industry
- ANL
- BYSI Biotechnology: Pharmaceutical Preparations
- Sector
- ANL
- BYSI Health Care
- Exchange
- ANL Nasdaq
- BYSI Nasdaq
- Market Cap
- ANL 84.5M
- BYSI 68.5M
- IPO Year
- ANL 2023
- BYSI 2017
- Fundamental
- Price
- ANL $2.14
- BYSI $1.63
- Analyst Decision
- ANL Strong Buy
- BYSI
- Analyst Count
- ANL 2
- BYSI 0
- Target Price
- ANL $9.00
- BYSI N/A
- AVG Volume (30 Days)
- ANL 9.6K
- BYSI 28.4K
- Earning Date
- ANL 08-08-2024
- BYSI 01-01-0001
- Dividend Yield
- ANL N/A
- BYSI N/A
- EPS Growth
- ANL N/A
- BYSI N/A
- EPS
- ANL N/A
- BYSI N/A
- Revenue
- ANL $5,000,000.00
- BYSI $1,876,000.00
- Revenue This Year
- ANL N/A
- BYSI N/A
- Revenue Next Year
- ANL N/A
- BYSI N/A
- P/E Ratio
- ANL N/A
- BYSI N/A
- Revenue Growth
- ANL N/A
- BYSI 21.03
- 52 Week Low
- ANL $1.85
- BYSI $0.78
- 52 Week High
- ANL $17.48
- BYSI $4.00
- Technical
- Relative Strength Index (RSI)
- ANL 43.45
- BYSI 40.58
- Support Level
- ANL $2.23
- BYSI $1.55
- Resistance Level
- ANL $2.44
- BYSI $1.84
- Average True Range (ATR)
- ANL 0.19
- BYSI 0.19
- MACD
- ANL -0.01
- BYSI 0.00
- Stochastic Oscillator
- ANL 23.43
- BYSI 10.96
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It has two reportable segments Plinabulin pipeline and the TPD platform.